Hong Kong-based Hutchinson China MediTech announced this week it filed an amended F-1 form with the U.S. Securities and Exchange Commission for its planned $100 million IPO in which it plans to sell American depositary shares under the symbol HCM.
China Resources Pharmaceutical Group, part of the state-owned mega-corporation China Resources, is planning to tap the capital markets in Hong Kong for a $1 billion initial public offering, according to a report by Reuters.
Motif Bio has appointed an investment bank to look into raising cash in the U.S., potentially through an IPO on Nasdaq. The action was prompted by a desire to tap into the deep pool of capital managed by specialist biotech investors in the U.S., while also trying to close a perceived valuation gap between Motif Bio and its Nasdaq-traded peers.
Details on the initial public offering for Beijing-based biotech BeiGene are out with the offer topping the $100 million early estimate and insiders slated to take more than half in an offering that will be closely watched as sentiment gauge for other China-focused biotech firms into the U.S. market.
As China tries to reform its healthcare system, companies are rushing in to tap the capital markets to expand their reach. The latest one to hit the market will be Jiangsu Hansoh Pharmaceutical, which plans to sell up to $3 billion in shares on the Hong Kong market, which, if successful, would be the largest healthcare IPO to hit the Hang Seng Index, according to data from Dealogic, cited in a Wall Street Journal report.
Looking to raise more than $86 million, Danish vaccinemaker Bavarian Nordic filed for a Nasdaq IPO this week on the heels of a busy 2015.
Look back on 2015 and you'll see an industry that has come into its own. With billions of dollars flowing in from IPOs, follow-ons, venture investors, the rich (those high net worth individuals), and pharma deals, there's never been a better time to start a new biotech company focused on making a leap in medicine. Provided, of course, that you're working with technology from a top institution and have some top VCs sending you Christmas cards.
Last year at this time I ended up predicting that we'd see things cool down on the IPO side. Going into the third year of a biotechapalooza of initial public offerings from newly minted companies looked overheated and overwrought. Initially, though, the market seemed completely indifferent to my thoughts on the subject (funny how that happens) and steamed ahead with bigger and bigger valuations on less and less evidence of potential. Then, when I was looking for a calm, practical slowdown, we got more of a head-on collision followed by a stunned silence.
China's YiChang HEC ChangJiang Pharmaceutical launched book-building on Tuesday for its planned HK$1.67 billion ($215 million) initial public offering and the company said it has lined up four cornerstone investors that will contribute $80 million.
A pair of Indian IPOs raised over $300 million this week and demonstrated that the country's pharmaceutical industry remains in demand for institutional investors.